live attenuated varicella vaccine
Trade name: Varivax
Approved
Mar 17, 1995
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine are more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of the disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin. Another vaccine, known as zoster vaccine, is used to prevent diseases caused by the same virus – the varicella zoster virus. — Wikipedia
Clinical trial activity
148 trials · 67 clinical orgs · 1 marketing orgs
Earliest trial started Feb 1, 1998 (NCT00005009)
Timeline
Indications
Approved for
Studied for
- Arthritis · Phase 2
- Arthritis, Psoriatic · Phase 2
- Arthritis, Rheumatoid · Phase 2
- Asthma · Phase 4
- Chickenpox · Phase 4
- Chickenpox Vaccine · Phase 3
- Crohn Disease · Phase 2
- Dengue · Phase 2
- Diphtheria · Phase 3
- Diphtheria Toxoid · Phase 2
- Encephalitis, Japanese · Phase 4
- Esophageal and Gastric Varices · Phase 4
- Fibrosis · Phase 4
- Haemophilus influenzae · Phase 2
- Haemophilus influenzae type b · Phase 3
- Healthy Volunteers · Phase 4
- Hemorrhoids · Phase 3
- Hepatitis A · Phase 3
- Hepatitis B · Phase 2
- Herpes Zoster · Phase 4
- Herpes Zoster Vaccine · Phase 4
- HIV Infections · Phase 2
- Immunization · Phase 1
- Immunosenescence · Phase 1
- Immunosuppression Therapy · Phase 3
- Inflammation · Phase 2
- Inflammatory Bowel Diseases · Phase 4
- Influenza, Human · Phase 3
- Influenza Vaccines · Phase 4
- Kidney Transplantation · Phase 4
- Lupus Erythematosus, Systemic · Phase 4
- Measles · Phase 3
- Measles-Mumps-Rubella Vaccine · Phase 3
- Meningitis · Phase 3
- Meningitis, Meningococcal · Phase 3
- Meningococcal Infections · Phase 3
- Mumps · Phase 3
- Mumps Vaccine · Phase 2
- Neisseria meningitidis · Phase 3
- Neuralgia, Postherpetic · Phase 3
- Organ Transplantation · Phase 3
- Pertussis Vaccine · Phase 3
- Pneumococcal Infections · Phase 3
- Pneumococcal Vaccines · Phase 3
- Pneumonia · Phase 3
- Poliomyelitis · Phase 3
- Poliovirus Vaccines · Phase 2
- Psoriasis · Phase 4
- Rubella · Phase 3
- Rubella Vaccine · Phase 2
- Severe Dengue · Phase 2
- Spondylitis, Ankylosing · Phase 2
- Tetanus · Phase 3
- Varicella Zoster Virus Infection · Phase 3
- Venous Insufficiency · Phase 3
- Whooping Cough · Phase 3
Mechanism of action
- Human herpesvirus 3Immunity, active
Human herpesvirus 3 immunity, active
Approval history
- approvedMar 17, 1995
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVaricella vaccine ↗
- NCATSGPV39ZGD8C ↗
- WikipediaZoster vaccine ↗
Also known as
- gsk209762
- herpes zoster vaccine
- live attenuated herpes zoster vaccine
- live attenuated vaccine against varicella
- live attenuated varicella vaccine
- live attenuated varicella virus vaccine
- live-attenuated varicella-zoster virus vaccine
- memuru-oka
- oka-merck
- okavax
- varicella virus vaccine live
- varicella virus vaccine live
- varicella zoster vaccine
- varicella-zoster vaccine
- varicella-zoster virus (live, attenuated)
- varivax
- varivax
- zostavax
- zostavax
- zoster vaccine, live
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07054099 | Phase 3 | Mar 31, 2026 | Green Cross Corporation |
| NCT07293065 | Phase 3 | Dec 19, 2025 | MAXVAX Biotechnology Limited Liability Company |
| NCT07311148 | Phase 2 | Oct 23, 2025 | Government of China |
| NCT06961721 | Phase 4 | May 31, 2025 | Changchun BCHT Biotechnology Co., Government of China |
| NCT06975878 | Phase 3 | May 22, 2025 | Sanofi |
| NCT06874842 | Phase 1 | Mar 13, 2025 | Government of China |
| NCT06824181 | Phase 3 | Feb 27, 2025 | Sanofi |
| NCT06824194 | Phase 3 | Feb 18, 2025 | Sanofi |
| NCT06851832 | Phase 1/Phase 2 (Phase 2) | Feb 16, 2025 | Ab&b Biotechnology Co., Ltd., Government of China |
| NCT06740630 | Phase 3 | Dec 17, 2024 | GlaxoSmithKline |
| NCT06736041 | Phase 3 | Dec 16, 2024 | Sanofi-Aventis |
| NCT06654700 | Phase 3 | Dec 9, 2024 | Government of China, MAXVAX Biotechnology Limited Liability Company |
| NCT06224270 | Phase 4 | Oct 31, 2024 | GlaxoSmithKline, University of Wisconsin |
| NCT06484686 | Phase 4 | Sep 30, 2024 | Government of China, Sinovac Biotech Co., Ltd |
| NCT06987942 | Phase 4 | Sep 21, 2024 | Sinovac Biotech Co., Ltd |
| NCT06447779 | Phase 3 | Jul 13, 2024 | Government of China, MAXVAX Biotechnology Limited Liability Company |
| NCT06335849 | Phase 1 | Mar 27, 2024 | Government of China, Nucleus Network Ltd |
| NCT06314724 | Phase 3 | Mar 1, 2024 | Sinovac Biotech Co., Ltd |
| NCT05839301 | Phase 3 | Apr 27, 2023 | Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, Government of China |
| NCT05794230 | Phase 3 | Mar 27, 2023 | Sanofi-Aventis |
Organizations
Research & Development (67)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 43 | 36 | 5 | 1998 |
| Government of China | Government | 28 | 7 | 4 | 2011 |
| GlaxoSmithKline | For profit | 18 | 16 | 4 | 2003 |
| Sinovac Biotech Co., Ltd | For profit | 12 | 12 | 3 | 2014 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 10 | 5 | 5 | 1998 |
| Sanofi-Aventis | For profit | 10 | 4 | 4 | 2005 |
| Sanofi | For profit | 9 | 9 | 3 | 2009 |
| China National Biotec Group Co., Ltd | For profit | 5 | 4 | 3 | 2012 |
| SK Chemicals | For profit | 5 | 5 | 3 | 2012 |
| Korea University | Academic/Hospital | 4 | 0 | 3 | 2012 |
| University of Colorado, Denver | Academic/Hospital | 4 | 3 | 3 | 2010 |
| Changchun Keygen Biological Products Co., Ltd. | For profit | 3 | 3 | 1 | 2013 |
| Green Cross Corporation | For profit | 3 | 3 | 3 | 2015 |
| MAXVAX Biotechnology Limited Liability Company | For profit | 3 | 3 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 1 | 1998 |
| Oregon Health and Science University | Academic/Hospital | 3 | 1 | 1 | 2013 |
| University of Alabama, Birmingham | Academic/Hospital | 3 | 2 | 1 | 2013 |
| University of Toronto | Academic/Hospital | 3 | 3 | 2 | 1999 |
| Beijing Tiantan Bio Co., Ltd | For profit | 2 | 0 | 1 | 2022 |
| Changchun BCHT Biotechnology Co. | For profit | 2 | 2 | 2 | 2020 |
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Merck | For profit | NDA | Mar 17, 1995 |